Group 1 - The core point of the article is that JingTai Holdings (02228.HK) has signed a letter of intent for collaboration with DoveTree LLC, focusing on AI and robotics in drug discovery for various diseases [1] - The collaboration will involve the development of small molecules and antibody candidates targeting oncology, autoimmune diseases, and neurological disorders [1] - JingTai Holdings will receive initial payments of $51 million and $49 million within 10 and 180 days after the final agreement, respectively, along with potential milestone payments worth billions and royalties based on annual net sales [1] Group 2 - Gregory Verdine, a prominent figure in chemical biology and a serial entrepreneur, founded DoveTree LLC and has established over ten biotech companies, including five publicly traded ones [2] - Verdine has led the approval of three therapeutic methods by the FDA and currently serves as a partner at Andreessen Horowitz, advising top research institutions [2] - The collaboration aims to enhance JingTai Holdings' AI and robotics capabilities in drug discovery, potentially leading to breakthrough therapies for patients worldwide [2]
晶泰控股(02228.HK)与哈佛教授创立的DoveTree达成合作 首付款1亿美元撬动数十亿美元潜在里程碑